Society for Immunotherapy of Cancer’s (SITC) 2021 Poster Resources

Attendee at Society for Immunotherapy of Cancer’s (SITC) 36TH Annual Meeting

The Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference Programs gathers world-renowned experts in the field to discover breakthroughs and progress research.

The industry’s largest conference features international leaders from academia, regulatory, and government agencies, and industry representatives and provides a multidisciplinary, educational, and interactive environment focused on improving outcomes for cancer patients. We are pleased to contribute to the scientific program via the posters and scientific symposia outlined below.

#943: 3D In Vitro Tumor Model Platform Rapidly Assays Immunotherapy Efficacy with High Content Imaging and Downstream Phenotypic Changes with Flow Cytometry and Cytokine Analysis
Charles River in Collaboration with Cypre

#555: A High-Throughput In Situ Screen to Identify Synergistic Combinations of Immune-Oncology Drugs with Targeted and Cytotoxic Agents in a Patient-Derived Humanized Mouse Model of Renal Cancer
Charles River in Collaboration with Kibur Medical

#142: Enhanced Antitumoral Activity of HER2-CAR-ts in Comparison to Trastuzumab in a Live Cell Imaging Supported 3d Assay
Julia Schueler, Research Director, Charles River

#149: In Vitro Efficacy Studies to Support Engineered T Cell Therapies
Sabrina de Munnik, Senior Scientist, Charles River

#148: Primary or iPSC-Derived Cell-Based Cytotoxicity Assays to Assess Potential Safety Risks of Engineered T Cell Therapies In Vitro
Sophie Vermond, Scientist, Charles River

pcr plate in a laboratory

Explore More Oncology Resources:

Check out our Oncology Tools & Resources…

Browse The Resources

SITC 2021 ePoster Presentations

3D in vitro tumor model platform rapidly assays immunotherapy efficacy with high content imaging and downstream phenotypic changes with flow cytometry and cytokine analysis
Presented by Julia Schueler



Download the PDF

A high-throughput in situ screen to identify synergistic combinations of immune-oncology drugs with targeted and cytotoxic agents in a patient-derived humanized mouse model of renal cancer 
Presented by Julia Schueler



Download the PDF


Enhanced antitumoral activity of HER2-CAR-Ts in comparison to Trastuzumab in a live cell imaging supported 3D assay
Presented by Julia Schueler



Download the PDF


In vitro efficacy studies to support engineered T cell therapies
Presented by Sabrina de Munnik



Download the PDF


Primary or iPSC-derived cell-based cytotoxicity assays to assess potential safety risks of engineered T cell therapies in vitro
Presented by Sophie Vermond



Download the PDF